Ruthenium-Catalyzed Para-Selective Oxidative Cross-Coupling of Arenes and Cycloalkanes
作者:Xiangyu Guo、Chao-Jun Li
DOI:10.1021/ol202081c
日期:2011.10.7
A novel, direct para-selective oxidativecross-coupling of benzene derivatives with cycloalkanes catalyzed by ruthenium was developed. A wide range of arenes bearing electron-withdrawing substituents was functionalized directly with simple cycloalkanes with high para-selectivity; arenes with electron-donating groups were mainly para-functionalized. Benzoic acid can be used directly.
compounds in which 5-chloroanthranilic acid was bound to a variety of highly lipophilic moieties with appropriate linkers was investigated. As the result it appeared that some of the derivatives possessing aryl- or heteroaryl-substituted phenyl groups in the acyl chain had potent in vitro PAI-1 inhibitoryactivity. Oral absorbability of typical compounds was also evaluated in rats, and compounds 40,
The present invention provides a novel compound having plasminogen activator inhibitor-1 inhibitory activity, and an inhibitor of PAI-1 comprising the compound as an active ingredient. The present invention also provides a pharmaceutical composition having an inhibitory action on PAI-1 activity and being efficacious in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity.
[EN] MALT1 MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE MALT1 ET LEURS UTILISATIONS
申请人:RHEOS MEDICINES INC
公开号:WO2021138298A1
公开(公告)日:2021-07-08
Provided herein are compounds, compositions, and methods useful for modulating MALT1 and for treating related diseases, disorders, and conditions.
本文提供了一些有用于调节MALT1并用于治疗相关疾病、疾病和症状的化合物、组合物和方法。
PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR
申请人:RENASCIENCE CO., LTD.
公开号:US20140296256A1
公开(公告)日:2014-10-02
The present invention provides a novel compound having plasminogen activator inhibitor-1 inhibitory activity, and an inhibitor of PAI-1 comprising the compound as an active ingredient. The present invention also provides a pharmaceutical composition having an inhibitory action on PAI-1 activity and being efficacious in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity.